SCHEMBL26078550

SCHEMBL26078550

FC(F)Oc1cc(Cl)ccc1CC1=NCCN1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRA2C P18825 6/20 0.43
▸ ADRA1A P35348 6/20 0.43
▸ ADRA2A P08913 5/20 0.43
▸ ADRA1D P25100 5/20 0.43
▸ ADRA1B P35368 5/20 0.43
▸ HTR1B P28222 4/20 0.43
▸ ADRA2B P18089 4/20 0.43
▸ HTR1D P28221 3/20 0.43
▸ TAAR1 Q96RJ0 6/20 0.43
▸ MAPK1 P28482 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ CYP2D6 P10635 2/20 0.40
▸ NISCH Q9Y2I1 2/20 0.40
▸ HTR1A P08908 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ OPRM1 P35372 1/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MAOA P21397 1/20 0.39
▸ MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26078529 0.87 NISCH (0.51) ADRA2CADRA1AADRA2AADRA1DADRA1B
SCHEMBL26078454 0.83 HTR1B (0.49) ADRA2CADRA1AADRA2AADRA1DADRA1B
SCHEMBL26078506 0.82 ADRA2A (0.46) ADRA2CADRA1AADRA2AADRA1DADRA1B
SCHEMBL26078499 0.80 ADRA2C (0.46) ADRA2CADRA1AADRA2AADRA1DADRA1B
SCHEMBL26078385 0.80 TAAR1 (0.49) ADRA2CADRA1AADRA2AADRA1DADRA1B
SCHEMBL26078581 0.80 TAAR1 (0.46) ADRA2CADRA1AADRA2AADRA1DADRA1B
SCHEMBL26078594 0.78 HTR1D (0.48) ADRA2CADRA1AADRA2AADRA1DADRA1B
SCHEMBL26078611 0.78 HTR1D (0.48) ADRA2CADRA1AADRA2AADRA1DADRA1B
SCHEMBL26078386 0.77 TAAR1 (0.46) ADRA2CADRA1AADRA2AADRA1DADRA1B
SCHEMBL26078494 0.77 ADRA2C (0.48) ADRA2CADRA1AADRA2AADRA1DADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312524-A1 ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE CURASEN THERAPEUTICS, INC. 2023-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312524-A1 ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE ADRA1A, ADRB1, ADRA1D ADRA2C 8/4885ADRA1A 1/4885ADRA2A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback